Published in J Clin Pharmacol on November 27, 2013
Opinion: Focus on preclinical sex differences will not address women's and men's health disparities. Proc Natl Acad Sci U S A (2015) 1.01
Sex differences in the brain: a whole body perspective. Biol Sex Differ (2015) 0.82
Our evolving science: studying the influence of sex in preclinical research. Biol Sex Differ (2016) 0.79
Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem. J Clin Sleep Med (2015) 0.79
Sex and the Lab: An Alcohol-Focused Commentary on the NIH Initiative to Balance Sex in Cell and Animal Studies. Alcohol Clin Exp Res (2016) 0.78
Zolpidem use and motor vehicle collisions in older drivers. Sleep Med (2015) 0.77
Sex and gender in medical education: a national student survey. Biol Sex Differ (2016) 0.75
Training emergency physicians in sex- and gender-based medicine: assessing attitudes of program directors and residency graduates. Biol Sex Differ (2016) 0.75
Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans. J Clin Sleep Med (2016) 0.75
Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. SAGE Open Med (2017) 0.75
Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. Front Pharmacol (2016) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
History of the development of sleep medicine in the United States. J Clin Sleep Med (2005) 4.22
Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep (2004) 3.78
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Sleep loss and REM sleep loss are hyperalgesic. Sleep (2006) 3.03
Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res (2002) 2.99
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry (2006) 2.86
The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res (2006) 2.60
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med (2005) 2.51
Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res (2002) 2.48
Early CPAP use identifies subsequent adherence to CPAP therapy. Sleep (2007) 2.19
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther (2010) 2.19
Sleep in lifetime posttraumatic stress disorder: a community-based polysomnographic study. Arch Gen Psychiatry (2004) 2.13
Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics (2006) 2.06
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
The association between obesity and short sleep duration: a population-based study. J Clin Sleep Med (2005) 1.87
The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep (2003) 1.86
Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep (2004) 1.84
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology (2012) 1.83
Insomnia and the performance of US workers: results from the America insomnia survey. Sleep (2011) 1.77
Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev (2001) 1.75
Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol (2009) 1.73
Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med (2010) 1.73
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep (2007) 1.72
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet (2008) 1.72
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety (2003) 1.54
Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry (2008) 1.51
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol (2005) 1.48
Patient-reported outcomes in insomnia: development of a conceptual framework and endpoint model. Behav Sleep Med (2013) 1.43
Caffeine: sleep and daytime sleepiness. Sleep Med Rev (2007) 1.41
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol (2003) 1.40
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc (2009) 1.38
Sleep during titration predicts continuous positive airway pressure compliance. Sleep (2003) 1.37
Sleep and pain: interaction of two vital functions. Semin Neurol (2005) 1.37
Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep (2011) 1.35
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry (2010) 1.29
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin (2004) 1.29
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin (2006) 1.28
Sleep hygiene practices in a population-based sample of insomniacs. Sleep (2005) 1.26
The 10-year risk of verified motor vehicle crashes in relation to physiologic sleepiness. Sleep (2010) 1.25
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med (2011) 1.24
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther (2003) 1.19
Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep (2011) 1.19
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med (2007) 1.17
Ethanol and sleep loss: a "dose" comparison of impairing effects. Sleep (2003) 1.17
The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep (2006) 1.17
Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics (2006) 1.16
Shift work sleep disorder: burden of illness and approaches to management. Drugs (2006) 1.15
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry (2008) 1.15
Zolpidem for insomnia. Expert Opin Pharmacother (2012) 1.14
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep (2008) 1.13
Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol (2004) 1.13
MSLT in primary insomnia: stability and relation to nocturnal sleep. Sleep (2011) 1.13
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry (2010) 1.13
Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann Clin Psychiatry (2008) 1.12
Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Clin Drug Investig (2013) 1.10
Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol (2002) 1.09
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol (2006) 1.09
Reliability and validity of the brief insomnia questionnaire in the America insomnia survey. Sleep (2010) 1.08
The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry (2012) 1.07
Consequences of shiftworking on sleep duration, sleepiness, and sleep attacks. Chronobiol Int (2010) 1.07
Stress-related sleep disturbance and polysomnographic response to caffeine. Sleep Med (2006) 1.06
Insomnia pharmacotherapy. Neurotherapeutics (2012) 1.05
Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement? Sleep (2006) 1.04
Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol (2008) 1.03
Sleep reactivity and insomnia: genetic and environmental influences. Sleep (2011) 1.03
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol (2013) 1.02
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath (2007) 1.02
Pain sensitivity in sleepy pain-free normals. Sleep (2009) 1.02
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med (2007) 1.01
Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol (2008) 1.01
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2011) 1.01
Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol (2003) 1.01
The venom composition of the parasitic wasp Chelonus inanitus resolved by combined expressed sequence tags analysis and proteomic approach. BMC Genomics (2010) 1.00
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry (2008) 0.99
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep (2011) 0.99
Pain sensitivity and recovery from mild chronic sleep loss. Sleep (2012) 0.99
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 0.99
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol (2007) 0.98
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol (2007) 0.97
Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep (2010) 0.97
Cortical locations of maximal spindle activity: magnetoencephalography (MEG) study. J Sleep Res (2009) 0.97
'Hypnotic' prescription patterns in a large managed-care population. Sleep Med (2004) 0.97
Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance. Neuropsychopharmacology (2002) 0.96
Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorder. Chronobiol Int (2012) 0.96
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep (2009) 0.96
Vulnerability to insomnia: the role of familial aggregation. Sleep Med (2007) 0.96
Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep (2012) 0.95
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord (2012) 0.95
Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol (2013) 0.95
Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology (Berl) (2011) 0.95